Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety of Aclidinium Bromide at Two Dose Levels vs Placebo When Administered to Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD).

Trial Profile

Efficacy and Safety of Aclidinium Bromide at Two Dose Levels vs Placebo When Administered to Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD).

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aclidinium bromide (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Acronyms ATTAIN
  • Sponsors Almirall S.A.
  • Most Recent Events

    • 22 May 2013 Results presented at the 109th International Conference of the American Thoracic Society.
    • 05 Sep 2012 Effects of treatment on disease exacerbations presented at the 22nd Annual Congress of the European Respiratory Society.
    • 22 Mar 2012 Full results were published in the European Respiratory Journal, according to a Almirall media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top